<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401492</url>
  </required_header>
  <id_info>
    <org_study_id>MILES-02</org_study_id>
    <nct_id>NCT00401492</nct_id>
  </id_info>
  <brief_title>MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to describe activity and toxicity of single-agent
      gemcitabine given as prolonged infusion, and of two 2-drug combinations containing cisplatin
      (cisplatin + vinorelbine, and cisplatin + gemcitabine) in the treatment of elderly patients
      with advanced non small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design includes three parallel phase II studies, all with the same rules for
      patient selection and outcome assessment. In the two studies of cisplatin-based doublets, a
      dose-finding phase is planned, with subsequent cohorts of 6 patients treated with increasing
      doses of cisplatin (50-60-70 mg/m²). Following this phase, patients will be assigned to the
      three studies through a randomization procedure, to reduce selection biases.

      Arm A: gemcitabine:

      Gemcitabine 1200 mg/m2 intravenously in 2 hours (10 mg/m²/minute) on days 1 &amp; 8 of each
      cycle, every 21 days, for a maximum of 6 cycles.

      Arm B: cisplatin + vinorelbine:

      Vinorelbine 25 mg/m² on days 1 &amp; 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1 of
      each cycle, every 21 days, for a maximum of 6 cycles.

      Arm C: cisplatin + gemcitabine:

      Gemcitabine 1000 mg/m2,, on days 1 &amp; 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1
      of each cycle, every 21 days, for a maximum of 6 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity and toxicity of monochemotherapy with gemcitabine as prolonged infusion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity and activity of 2 standard polychemotherapy cisplatin based treatments (cisplatin and vinorelbine , and cisplatin and gemcitabine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prognostic significance of the ADL and IADL scales for time to progression and survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory predictive clinical variables for chemotherapy related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory predictive clinical variables for response to chemotherapy</measure>
  </secondary_outcome>
  <enrollment type="Actual">159</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine prolonged continuous infusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of NSCLC

          -  Stage IV or IIIB with pleural effusion or metastatic supraclavicular lymphoadenopathy

          -  Age &gt; o = 70 years.

          -  Written informed consent.

        Exclusion Criteria:

          -  Performance status (ECOG) ³2

          -  Previous chemotherapy.

          -  Symptomatic brain metastases requiring synchronous radiotherapy

          -  Previous radiotherapy (completed less than 4 weeks before enrollment)

          -  Previous or synchronous malignant disease (except adequately treated non melanomatous
             skin cancer or carcinoma in situ of the cervix) if diagnosed in the last five years
             before enrollment.

          -  Neutrophils &lt; 2.000/mm³ or platelets &lt; 100.000/mm³ or hemoglobin &lt; 10 g/dl.

          -  Serum creatinine &gt; 1.5 times the UNL.

          -  GOT and/or GPT &gt;1.25 times the UNL or serum total bilirubin &gt;1.25 times the UNL
             without hepatic metastases.

          -  GOT and/or GPT &gt;2.5 times the UNL or serum total bilirubin &gt;1.5 times the UNL with
             hepatic metastases.

          -  Other concomitant diseases contraindicating the study treatments.

          -  Refusal of written informed consent.

          -  Follow-up impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Giuseppe Moscati Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples Italy</affiliation>
  </overall_official>
  <results_reference>
    <citation>Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lorusso V, Carrozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007 Oct 10;25(29):4663-9.</citation>
    <PMID>17925563</PMID>
  </results_reference>
  <results_reference>
    <citation>Gridelli C, De Maio E, Barbera S, Sannicolo M, Piazza E, Piantedosi F, Brancaccio L, Morabito A, Maione P, Renda F, Signoriello G, Perrone F; MILES Investigators. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Lung Cancer. 2008 Jul;61(1):67-72.</citation>
    <PMID>18683299</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elderly</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>ADL</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

